At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 77 enrolled

Drug / intervention

Placebo +1 moredrug

Likely dose

Candesartan 8 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02646982

NCT02646982Phase 2Completed

Compare CT.gov

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Emory University·interventional·Posted Jan 6, 2016·Updated Dec 1, 2022

In Brief

A Phase 2 clinical trial evaluating Placebo and Candesartan for Mild Cognitive Impairment. Completed, enrolled 77 participants across 2 sites.

Detailed Summary

This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMild Cognitive Impairment

CountriesUnited States

CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished

20162017201820192020202120222023202420252026

First PostedJan 2016

Enrollment StartJun 2016

Primary CompletionAug 2020

TodayJul 2026

First PostedJan 6, 2016

Enrollment StartJun 30, 2016

Primary CompletionAug 17, 2020

TodayJul 2, 2026

Enrollment to primary: 4.1 yearsPosted 10.5 years ago

Interventions

Placebodrug

A matched placebo will be given once daily for 12 months.

Candesartandrug

Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.